Detalles de la búsqueda
1.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis;
77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
2.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med;
382(12): 1124-1135, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130806
3.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med;
382(12): 1112-1123, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130809
4.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
Antimicrob Agents Chemother;
66(2): e0091621, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34871089
5.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet;
396(10267): 1994-2005, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308425
6.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav;
24(12): 3533-3544, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32447500
7.
Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Antimicrob Agents Chemother;
62(9)2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29987139
8.
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Clin Infect Dis;
59(3): 425-34, 2014 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24729492
9.
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Antivir Ther;
29(2): 13596535241248282, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38725258
10.
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Clin Pharmacol Drug Dev;
12(11): 1060-1068, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335552
11.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet;
378(9787): 229-37, 2011 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21763935
12.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet;
378(9787): 238-46, 2011 Jul 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21763936
13.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
J Antimicrob Chemother;
67(8): 2020-8, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22532465
14.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS;
36(2): 185-194, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34261093
15.
The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Drug Saf;
44(4): 439-446, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367975
16.
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
Antivir Ther;
26(6-8): 95-105, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35485339
17.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient;
14(6): 849-862, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34056699
18.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
AIDS;
35(9): 1413-1421, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33831904
19.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS;
35(9): 1333-1342, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33730748
20.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV;
8(11): e679-e689, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648734